Quantcast

Latest Exenatide Stories

2015-05-15 16:24:49

- CEO Kurt Graves interviewed by Jim Cramer on CNBC's "Mad Money" as one of the companies named to the important list of "Disruptors" BOSTON, May 15, 2015 /PRNewswire/ --

2015-05-04 08:30:00

- New Chief Operating Officer position has full accountability for taking the lead in building out novel go-to-market model, commercial capabilities and operational plans for ITCA 650.

2015-05-01 16:31:34

- New role increases Company's ability to drive optimal performance through people strategy, organizational effectiveness, learning & development, and a values-based work environment -

2015-04-28 00:23:14

- Company secures $225M financing in exchange for 1.5% of future global net sales of ITCA 650, a novel once or twice yearly and injection-free GLP-1 therapy currently in phase 3 clinical development

2015-03-19 16:29:53

-- Collaboration combines Intarcia's proprietary delivery technologies with Numab's novel multi-specific antibody technology to broaden and strengthen Intarcia's pipeline BOSTON and

2015-01-16 08:25:17

JERUSALEM, January 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

2014-12-21 23:00:57

Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California. New

2014-12-07 23:01:20

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin

2014-12-02 12:31:26

The Lack of Reimbursement for DPP-IV Inhibitors and GLP-1 Analogues Hinders Their Uptake Among Chinese Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., Dec.

2014-12-01 23:00:55

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related